Added to YB: 2026-09-14
Pitch date: 2026-09-11
RVPH [neutral]
Reviva Pharmaceuticals Holdings, Inc.
Author Info
I invest in dirty, uncomfortable, asymmetric setups, confounding situations and contra-narrative ideas, along with occasional fat pitch trend following and sidecar situations. Sign up for the newsletter.
Company Info
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Market Cap
$7.0M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-0.30
EV/Sales
N/A
Sector
Pharmaceuticals
Category
value
Scouting Brilaroxazine - Reviva Pharmaceuticals Holdings, Inc.
RVPH (overview): Reviva’s late-stage schizophrenia asset Brilaroxazine scores 3.15/5 in a CNS-acquisition model, implying a $715M benchmark strategic value versus Reviva’s roughly $6.6M basic market capitalization; Teva’s $700M upfront Emalex acquisition provides a close precedent. The asset has successful Phase 2 and Phase 3 results, but FDA-required RECOVER-2 could fail, long-term IP remains unproven, and financing, warrants and dilution may prevent much of any asset value from reaching current shareholders.
Read full article (6 min)